
Fabric Genomics (AKA: Omica Inc ) Profile last edited on: 7/3/19
CAGE: 47TJ5
UEI:
Business Identifier: Global healthcare platform: genomic data analysis focused on hereditary disease and oncology Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1611 Telegraph Avenue Suite 500
Oakland, CA 94612
Oakland, CA 94612
(510) 595-0800 |
info@fabricgenomics.com |
www.fabricgenomics.com |
Location: Single
Congr. District: 13
County: Alameda
Congr. District: 13
County: Alameda
Public Profile
Since March 2017 dba Fabric Genomics, - formerly Omicia, Inc.- the firm has re-branded itself to signal launch of fully-integrated and comprehensive genomic data analysis platform for all NGS testing. The firm is developing scalable and integrated informatics systems to interpret human genome sequences for research and clinical applications -- unlocking individualized medicine by translating data derived from whole-genome sequencing into actionable information for researchers and clinicians. Headquartered in Oakland, CA with offices in the U.K., Seattle, Salt Lake City, and Boston, Omicia was founded by scientists and industry veterans in bioinformatics, genomics and diagnostics. The firm maintains a comprehensive database of information about genetic variations related to health conditions and is pioneering new informatics approaches that enhance the power of predictive and preventive medicine. The firm is pioneering new informatics approaches that power next-gen sequencing applications for clinical testing, translational research, and drug development. Omicia's Opal⢠platform integrates genome analysis algorithms and automated clinical annotations, enabling labs to identify and report on disease-causing genes with unprecedented accuracy and efficienc
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2013 | 2 | NIH | $1,752,428 | |
Project Title: Clinical Genome Inference System: Variant Prioritization for Clinical Diagnostics | ||||
2010 | 1 | NIH | $149,168 | |
Project Title: Disease Annotations for Variants in Personal Genomes | ||||
2010 | 1 | NIH | $150,686 | |
Project Title: Genetic Hotspots for Disease Risk | ||||
2010 | 2 | NIH | $950,537 | |
Project Title: System to predict novel genetic disease associations | ||||
2010 | 2 | NIH | $1,118,937 | |
Project Title: Prototype system for genetic marker information delivery |
Key People / Management
Martin G Reese -- Co-founder, President & Chief Scientific Officer
Mike A Aicher -- Board of Directors
Joel S Bader
Paul Billings -- Chief Medical Officer
Trish Brown -- Vice President, Clinical Services
Karen L Eilbeck
Mahsa Ghafourian -- Development
Edward Kiruluta -- Co-founder & Chief Technology Officer
Vaness Sawyer -- Director of Marketing
Charlene Son Rigby -- Vice President, Products
John Stuelpnagel -- Co-founder, Board of Directors
Mike A Aicher -- Board of Directors
Joel S Bader
Paul Billings -- Chief Medical Officer
Trish Brown -- Vice President, Clinical Services
Karen L Eilbeck
Mahsa Ghafourian -- Development
Edward Kiruluta -- Co-founder & Chief Technology Officer
Vaness Sawyer -- Director of Marketing
Charlene Son Rigby -- Vice President, Products
John Stuelpnagel -- Co-founder, Board of Directors